ArticleInternational journal of colorectal disease2026
Mapping fibrosis in colorectal liver metastases (CRLM) with gadobenate dimeglumine-enhanced MRI: prognostic implications and imaging biomarkers.
Article in International journal of colorectal disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDevelopment of fibrosis in treated colorectal liver metastases (CRLM) could be supposedly used for the estimation of both treatment response and prognosis. This study aimed to investigate the association between post-chemotherapy, fibrosis-related progressive gadolinium enhancement of CRLM on MRI and overall survival. MATERIAL AND
methodsA retrospective study of 97 CRLM patients (68 M, mean age 62.3 ± 10.71 years) who underwent between 2017 and 2022 preoperative gadobenate dimeglumine (Gd-BOPTA) - enhanced MRI after chemotherapy. Tumor and liver enhancement were quantified using Signal Intensity Change Percentages (SICP) across 5-min and 60-min delay phases, along with the Tumor-to-Liver Enhancement Index (TLEI) to estimate fibrosis within CRLM. A subset of 18 patients was evaluated for radiologic-pathologic correlation. Cox regression, Kaplan-Meier analysis, and multivariate models were used to assess overall survival (OS).
resultsHigh SICP (≥ 90.3%) in the 60-min delayed phase was associated with significantly lower OS (median: 37 vs. 66 months; p = 0.023). TLEI was significantly elevated in non-survivors (1.25 vs. 1.10; p = 0.007). Histopathologic correlation, available in 18 patients, confirmed fibrosis in lesions with elevated SICP, though limited sample size precluded statistical validation. In multivariate analysis, both high TLEI and elevated SICP were independent predictors of reduced OS (HR 1.38 [1.05-1.82], p = 0.023; HR 1.01 [1.00-1.01], p = 0.043, respectively). Notably, aflibercept- and FOLFOX-4-treated patients showed higher fibrosis-associated enhancement.
conclusionGd-BOPTA-enhanced MRI, specifically SICP and TLEI in the delayed phase, may serve as non-invasive imaging biomarkers of fibrosis in CRLM. Contrary to prior assumptions, increased fibrosis was associated with worse prognosis, suggesting fibrosis-mediated tumor microenvironment alterations. Prospective studies with robust radiologic-pathologic validation are needed to clarify the mechanistic and prognostic implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.